347740 — P&K Skin Research Center Co Income Statement
0.000.00%
- KR₩95bn
- KR₩48bn
- KR₩15bn
- 93
- 30
- 87
- 85
Annual income statement for P&K Skin Research Center Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 12,499 | 14,676 | 17,487 | 17,957 | 14,843 |
Cost of Revenue | |||||
Gross Profit | 9,150 | 10,331 | 11,298 | 11,113 | 7,199 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 6,823 | 7,460 | 11,025 | 12,317 | 13,463 |
Operating Profit | 5,676 | 7,217 | 6,462 | 5,640 | 1,379 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 6,316 | 7,782 | 8,526 | 8,190 | 5,357 |
Provision for Income Taxes | |||||
Net Income After Taxes | 5,376 | 6,719 | 7,293 | 7,130 | 4,700 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 5,376 | 6,719 | 7,293 | 7,130 | 4,813 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 5,376 | 6,719 | 7,293 | 7,130 | 4,813 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 220 | 260 | 246 | 239 | 160 |
Dividends per Share |